Pipeline
Otsuka Pharmaceutical collaborates actively with leading-edge academia and venture companies, in addition to using conventional drug discovery methods.
This open sharing of ideas enables us to develop unique compounds.
Psychiatry & Neurology
(Phase I, II, III, Filed / Approved)
OPC-34712 FUM
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712 FUM
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712 FUM
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712 FUM
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712 FUM
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Depot injection
OPC-34712 FUM
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Once-weekly oral
<ABILIFY ASIMTUFII>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Depot injection
Origin: Otsuka Pharmaceutical
Dosage form: Oral
Origin: Avanir
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Origin: Neurovance
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
Origin: Neurovance
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
Origin: former Sunovion / PsychoGenics*
Features: TAAR1・5-HT1A agonist
Dosage form: Oral
*Sunovion discovered ulotaront (SEP-363856) in collaboration with PsychoGenics.
Origin: former Sunovion / PsychoGenics*
Features: TAAR1・5-HT1A agonist
Dosage form: Oral
*Sunovion discovered ulotaront (SEP-363856) in collaboration with PsychoGenics.
Origin: former Sunovion / PsychoGenics*
Features: TAAR1・5-HT1A agonist
Dosage form: Oral
*Sunovion discovered ulotaront (SEP-363856) in collaboration with PsychoGenics.
Origin: former Sunovion / PsychoGenics*
Features: TAAR1・5-HT1A agonist
Dosage form: Oral
*Sunovion discovered ulotaront (SEP-363856) in collaboration with PsychoGenics.
Oncology
(Phase I, II, III, Filed / Approved)
<INQOVI / INAQOVI>
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
<INQOVI / INAQOVI>
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
<INQOVI / INAQOVI>
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
Origin: Astex
Features: IAP inhibitor
Dosage form: Oral
decitabine, cedazuridine
Origin: Astex
Dosage form: Oral
Origin: Astex
Features: ERK1/2 inhibitor
Dosage form: Oral
Origin: Astex
Features: MDM2 inhibitor
Dosage form: Oral
Origin: Astex
Dosage form: Oral
<ICLUSIG>
Origin: Takeda Pharmaceutical
Features: BCR-ABL tyrosine kinase inhibitor
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Dosage form: Oral
Origin: Osaka University
Features: Activated integrin β7-targeted CAR-T cell therapy
Dosage form: Injection
Cardiovascular & Renal areas
(Phase I, II, III, Filed / Approved)
Origin: Visterra
Features: Anti-APRIL monoclonal antibody
Dosage form: Injection
Origin: Esperion
Features: ATP-citrate lyase inhibitor
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Features: V1a / V2 dual antagonist
Dosage form: Oral
Other therapeutic areas
(Phase I, II, III, Filed / Approved)
<Deltyba>
Features: Mycolic acid biosynthesis inhibitor
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Features: DprE1 inhibitor
Dosage form: Oral
<Moizerto>
Origin: Otsuka Pharmaceutical
Features: PDE4 inhibitor
Dosage form: Ointment
<Mikeluna>
Origin: Otsuka Pharmaceutical
Features: β receptor antagonist / PGF2α analogue
Dosage form: Eye drops
Origin: Otsuka Pharmaceutical
Features: DNA gyrase inhibitor
Dosage form: Oral
Origin: Visterra
Features: Modified interleukin-2 molecule designed to specifically activate and amplify regulatory T lymphocytes
Dosage form: Injection
(Phase I, II, III, Filed / Approved)
<INQOVI / INAQOVI>
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
OPC-34712 FUM
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712 FUM
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712 FUM
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
<ABILIFY ASIMTUFII>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Depot injection
<ICLUSIG>
Origin: Takeda Pharmaceutical
Features: BCR-ABL tyrosine kinase inhibitor
Dosage form: Oral
OPC-34712 FUM
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712 FUM
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Once-weekly oral
Origin: Avanir
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Origin: Neurovance
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
Origin: former Sunovion / PsychoGenics*
Features: TAAR1・5-HT1A agonist
Dosage form: Oral
*Sunovion discovered ulotaront (SEP-363856) in collaboration with PsychoGenics.
Origin: Visterra
Features: Anti-APRIL monoclonal antibody
Dosage form: Injection
Origin: Esperion
Features: ATP-citrate lyase inhibitor
Dosage form: Oral
<Deltyba>
Features: Mycolic acid biosynthesis inhibitor
Dosage form: Oral
<Moizerto>
Origin: Otsuka Pharmaceutical
Features: PDE4 inhibitor
Dosage form: Ointment
<Mikeluna>
Origin: Otsuka Pharmaceutical
Features: β receptor antagonist / PGF2α analogue
Dosage form: Eye drops
Origin: former Sunovion / PsychoGenics*
Features: TAAR1・5-HT1A agonist
Dosage form: Oral
*Sunovion discovered ulotaront (SEP-363856) in collaboration with PsychoGenics.
Origin: former Sunovion / PsychoGenics*
Features: TAAR1・5-HT1A agonist
Dosage form: Oral
*Sunovion discovered ulotaront (SEP-363856) in collaboration with PsychoGenics.
Origin: former Sunovion / PsychoGenics*
Features: TAAR1・5-HT1A agonist
Dosage form: Oral
*Sunovion discovered ulotaront (SEP-363856) in collaboration with PsychoGenics.
Origin: Neurovance
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
<INQOVI / INAQOVI>
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Features: V1a / V2 dual antagonist
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Features: DprE1 inhibitor
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Features: DNA gyrase inhibitor
Dosage form: Oral
Origin: Astex
Features: ERK1/2 inhibitor
Dosage form: Oral
Origin: Astex
Features: MDM2 inhibitor
Dosage form: Oral
Origin: Osaka University
Features: Activated integrin β7-targeted CAR-T cell therapy
Dosage form: Injection
OPC-34712 FUM
<REXULTI / RXULTI>
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Depot injection
Origin: Otsuka Pharmaceutical
Dosage form: Oral
<INQOVI / INAQOVI>
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
Origin: Astex
Features: IAP inhibitor
Dosage form: Oral
decitabine, cedazuridine
Origin: Astex
Dosage form: Oral
Origin: Astex
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Dosage form: Oral
Origin: Otsuka Pharmaceutical
Dosage form: Oral
Origin: Visterra
Features: Modified interleukin-2 molecule designed to specifically activate and amplify regulatory T lymphocytes
Dosage form: Injection
- Note: In general, Otsuka discloses clinical trial projects that are in Phase II or later stage of development, however, only clinical trial projects in Phase I conducted with patients are disclosed.
(as of October 31, 2023)